Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Concordia Healthcare Corp. T.CXR.R



TSX:CXR.R - Post by User

Comment by Lumberfeverlongon Aug 25, 2016 10:43pm
114 Views
Post# 25178802

RE:RE:Lumberfeverlong the self-proclaimed Securities Lawyer

RE:RE:Lumberfeverlong the self-proclaimed Securities Lawyer

Your numbers make no sense.  Again, even if they are right, which I do not agree they are, they are still cash flow positive with $140 million in cash and undrawn revolver. 


LaticelnExile wrote: Apologies, should have said they can only draw 30% ($60mil) without a convenant being triggered.

LaticelnExile wrote:

I am not responding to your post to LalliceinExcile, as that is another poster.  I would suggest that as a securities lawyer you should learn how to interpret financials.

it will be very tight in the near term:  

                                           (in millions)

Expected F16 Adj EBITDA    $525 ml   (taken from management)
Actual F16                               283
Actual Adj, EBITDA for H2      242

Est H1 F16 FCFF at 81.5% of EBITDA 

Therefore the F16 FCFF will be $197

Less Expected Interest for H2    ($120)

FCFE for H2                                 $77

Expected Cash for Hs                 $222 

Purchase Consideration Cinven ($210)
    
Less LtT Debt Payment              ($   9)

To that leaves the company with $3 mil cash remaining, which is TIGHT

The revolving loan is $200 milion but they can only draw 30% ($60mil) without a loan being triggered.

These numbers assume Donnatal is flat (which noone believes) and that they will not encounter pricing pressure.  So this is an extra 3 mil for H2 if the stars are aligned.

 





<< Previous
Bullboard Posts
Next >>